Physician profile
Tara Asher
NPI 1821336280
$6,106.27
in general payments reported to CMS, 2019-2025
23 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $889 · 2023: $1,111 · 2024: $1,595 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,622.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,464.90 | 2021-2025 | |
| Gilead Sciences, INC. | $921.04 | 2021-2025 | Descovy, Veklury, Livdelzi |
| Axsome Therapeutics, INC. | $373.07 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.49 | 2023-2025 | Jardiance |
| Genentech USA, INC. | $254.47 | 2021-2025 | Xolair |
| Amgen INC. | $254.38 | 2023-2025 | Krystexxa, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.22 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $247.71 | 2023-2024 | Yupelri, Yupelri |
| Otsuka America Pharmaceutical, INC. | $245.77 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $150.00 | 2025 | Invega Trinza, Invega Sustenna |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Biomerieux INC | $142.00 | 2025 | Biofire Respiratory Panel 2.1 |
| Luye Pharma (USA) LTD. | $130.00 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $128.88 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $125.00 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $123.66 | 2024 | Voquezna |
| Impel Pharmaceuticals INC. | $123.66 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $123.66 | 2021 | |
| Grifols USA, LLC | $122.91 | 2025 | Xembify |
| Alkermes, INC. | $116.82 | 2023 | Lybalvi |
| Biohaven Pharmaceuticals, INC. | $105.01 | 2021 | |
| Lilly USA, LLC | $101.88 | 2024 | |
| Novo Nordisk INC | $74.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.